Model Informed Drug Development and Regulation in China: Challenges and Opportunities.
作者信息
Li Li, Han Hongcan, Wang Jun, Wei Chunmin, Wang Yuzhu, Li Min, Zhou Yu, Yang Jinbo
机构信息
Office of Biostatistics and Clinical Pharmacology, Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):59-61. doi: 10.1002/psp4.12368. Epub 2019 Jan 4.
Abstract
摘要
相似文献
1
Model Informed Drug Development and Regulation in China: Challenges and Opportunities.中国的模型引导药物研发与监管：挑战与机遇
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):59-61. doi: 10.1002/psp4.12368. Epub 2019 Jan 4.
2
Recent Advances in Drug Development and Regulatory Science in China.中国药物研发与监管科学的最新进展
Ther Innov Regul Sci. 2018 Nov;52(6):739-750. doi: 10.1177/2168479018764661. Epub 2018 Apr 3.
3
Non-Procrustean pathways for complex generic drugs development.复杂通用药物开发的非强求一致途径。
Ther Deliv. 2018 Sep;9(9):605-607. doi: 10.4155/tde-2018-0047.
4
Generating Model Integrated Evidence for Generic Drug Development and Assessment.生成用于仿制药开发和评估的模型综合证据。
Clin Pharmacol Ther. 2019 Feb;105(2):338-349. doi: 10.1002/cpt.1282. Epub 2019 Jan 20.
5
Are Regulators Talking to Each Other Across Borders?监管机构正在跨境相互沟通吗？
Clin Pharmacol Ther. 2020 Mar;107(3):481-483. doi: 10.1002/cpt.1761.
6
Iberoamerican Pharmacometrics Network Congress 2018 Report: Fostering Modeling and Simulation Approaches for Drug Development and Regulatory and Clinical Applications in Latin America.2018年伊比利亚美洲药物计量学网络大会报告：促进拉丁美洲药物研发、监管及临床应用中的建模与模拟方法
CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):197-200. doi: 10.1002/psp4.12387. Epub 2019 Feb 22.
7
Defining orphan conditions in the context of the European orphan regulation: challenges and evolution.在欧洲孤儿药法规背景下定义罕见病：挑战与演变
Nat Rev Drug Discov. 2019 Jul;18(7):479-480. doi: 10.1038/nrd.2018.128.
8
Applications of Adaptive Designs in Generic Drug Development.适应性设计在仿制药开发中的应用。
Clin Pharmacol Ther. 2021 Jul;110(1):32-35. doi: 10.1002/cpt.2050. Epub 2020 Oct 14.
9
Application of Advanced Modeling Approaches Supporting Generic Product Development Under GDUFA for Fiscal Year 2023.2023财年在《药品用户费用法案》（GDUFA）下支持通用产品开发的先进建模方法的应用
AAPS J. 2024 Apr 24;26(3):55. doi: 10.1208/s12248-024-00924-8.
10
Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines.监管密度作为一种手段，用于改进当前针对日益复杂药物的监管方法。
Drug Discov Today. 2021 Oct;26(10):2221-2225. doi: 10.1016/j.drudis.2021.04.005. Epub 2021 Apr 20.
引用本文的文献
1
The effect of overuse by primary healthcare institutions on medical expenses: an empirical study from the western regions of China.基层医疗卫生机构过度使用对医疗费用的影响：来自中国西部地区的实证研究
Front Public Health. 2025 May 9;13:1588806. doi: 10.3389/fpubh.2025.1588806. eCollection 2025.
2
PBPK Modeling: Empowering Drug Development and Precision Dosing in China.生理药代动力学（PBPK）模型：助力中国药物研发与精准给药
CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):828-839. doi: 10.1002/psp4.70004. Epub 2025 Feb 18.
3
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.用于指导临床试验设计和监管决策的模型驱动药物发现与开发方法：中东和北非地区入门指南
Saudi Pharm J. 2024 Dec;32(12):102207. doi: 10.1016/j.jsps.2024.102207. Epub 2024 Nov 27.
4
Factors influencing willingness to participate in ophthalmic clinical trials and strategies for effective recruitment.影响参与眼科临床试验意愿的因素及有效招募策略。
Int J Ophthalmol. 2024 Jan 18;17(1):157-163. doi: 10.18240/ijo.2024.01.21. eCollection 2024.
5
Revisiting Supersaturation of a Biopharmaceutical Classification System IIB Drug: Evaluation via a Multi-Cup Dissolution Approach and Molecular Dynamic Simulation.重新审视生物制药分类系统 IIB 药物的过饱和度：通过多杯溶出方法和分子动力学模拟进行评估。
Molecules. 2023 Oct 7;28(19):6962. doi: 10.3390/molecules28196962.
6
Editorial: Model-informed drug development and evidence-based translational pharmacology.社论：模型指导的药物研发与循证转化药理学
Front Pharmacol. 2022 Dec 12;13:1086551. doi: 10.3389/fphar.2022.1086551. eCollection 2022.
7
Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions.模拟非药物 COVID-19 干预措施对呼吸道疾病临床试验的干扰。
Nat Commun. 2022 Apr 13;13(1):1980. doi: 10.1038/s41467-022-29534-8.
8
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.体外到体内外推与基于生理的药代动力学模型相关联，用于评估脑内药物处置。
AAPS J. 2022 Jan 13;24(1):28. doi: 10.1208/s12248-021-00675-w.
9
Regulatory utility of pharmacometrics in the development and evaluation of antimicrobial agents and its recent progress in China.药物代谢动力学在抗菌药物研发和评价中的监管作用及其在中国的最新进展。
CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1466-1478. doi: 10.1002/psp4.12716. Epub 2021 Oct 15.
10
Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate.开启开源建模工具的辩论：火上浇油还是扑灭健康辩论的火花。
CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):420-427. doi: 10.1002/psp4.12615. Epub 2021 May 1.
本文引用的文献
1
Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.日本药品和医疗器械管理局（PMDA）中的定量建模与模拟：日本监管视角
CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):413-415. doi: 10.1002/psp4.12203. Epub 2017 Jun 1.
2
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.模型引导的药物发现与开发中的良好实践：实践、应用与文档记录
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049. Epub 2016 Mar 14.
3
The utility of modeling and simulation in drug development and regulatory review.建模和模拟在药物研发和监管审查中的应用。
J Pharm Sci. 2013 Sep;102(9):2912-23. doi: 10.1002/jps.23570. Epub 2013 May 24.
4
Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.药物计量学分析对新药审批和标签决策的影响：2000 年至 2008 年间 198 项申报的回顾。
Clin Pharmacokinet. 2011 Oct;50(10):627-35. doi: 10.2165/11593210-000000000-00000.
5
Pharmacometrics for regulatory decision making: status and perspective.用于监管决策的药物计量学：现状与展望。
Clin Pharmacokinet. 2011 Oct;50(10):625-6. doi: 10.2165/11594340-000000000-00000.
Zotero 插件